Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
47
KROS Quote, Financials, Valuation and Earnings
Last price:
$16.61
Seasonality move
:
-4.37%
Day range:
$16.46 - $16.83
52-week range:
$9.12 - $22.55
Dividend yield:
0%
P/E ratio:
10.75x
P/S ratio:
2.73x
P/B ratio:
0.72x
Volume:
212.4K
Avg. volume:
327.9K
1-year change:
63.35%
Market cap:
$505.1M
Revenue:
$3.6M
EPS (TTM):
$1.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
|
$3.7M | -$0.45 | -99.81% | -60.42% | $23.00 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 29.62% | 267.32% | $14.50 |
|
INSM
Insmed, Inc.
|
$264M | -$1.16 | 191.33% | -43.17% | $214.37 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$156.1M | -$1.24 | 46.3% | -36.26% | $91.13 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 30.05% | 17.65% | $9.61 |
|
SRPT
Sarepta Therapeutics, Inc.
|
$391M | -$0.77 | -49.33% | -91.57% | $21.43 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
|
$16.58 | $23.00 | $505.1M | 10.75x | $0.00 | 0% | 2.73x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.31 | $14.50 | $4.5B | -- | $0.00 | 0% | 7.32x |
|
INSM
Insmed, Inc.
|
$148.75 | $214.37 | $31.7B | -- | $0.00 | 0% | 63.30x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$80.60 | $91.13 | $13.1B | -- | $0.00 | 0% | 13.72x |
|
MNKD
MannKind Corp.
|
$5.66 | $9.61 | $1.7B | 60.08x | $0.00 | 0% | 5.57x |
|
SRPT
Sarepta Therapeutics, Inc.
|
$17.79 | $21.43 | $1.9B | 20.50x | $0.00 | 0% | 0.76x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
|
2.42% | -0.669 | 2.71% | 28.93x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.293 | 18.22% | 1.91x |
|
INSM
Insmed, Inc.
|
44.07% | 2.488 | 2.43% | 4.18x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
76.83% | 2.779 | 19.43% | 2.51x |
|
MNKD
MannKind Corp.
|
124.56% | -0.068 | 13.7% | 2.54x |
|
SRPT
Sarepta Therapeutics, Inc.
|
48.64% | -0.463 | 61.92% | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
|
$13.9M | -$15.4M | 9.66% | 9.94% | -107.87% | $3.1M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$151.5M | -$160.2M | -9.92% | -43.01% | -102.21% | -$138.4M |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
|
SRPT
Sarepta Therapeutics, Inc.
|
$230.1M | -$62.9M | -10.24% | -20.67% | -15.75% | -$55.6M |
Keros Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns KROS or FOLD?
Amicus Therapeutics, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of 10.24%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About KROS or FOLD?
Keros Therapeutics, Inc. has a consensus price target of $23.00, signalling upside risk potential of 37.97%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.33%. Given that Keros Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Keros Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.5 4 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is KROS or FOLD More Risky?
Keros Therapeutics, Inc. has a beta of 0.857, which suggesting that the stock is 14.332% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.
-
Which is a Better Dividend Stock KROS or FOLD?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or FOLD?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Keros Therapeutics, Inc.'s net income of -$7.3M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 2.73x versus 7.32x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.2.73x 10.75x $14.3M -$7.3M FOLDAmicus Therapeutics, Inc.7.32x -- $169.1M $17.3M
-
Which has Higher Returns KROS or INSM?
Insmed, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of -259.95%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About KROS or INSM?
Keros Therapeutics, Inc. has a consensus price target of $23.00, signalling upside risk potential of 37.97%. On the other hand Insmed, Inc. has an analysts' consensus of $214.37 which suggests that it could grow by 44.11%. Given that Insmed, Inc. has higher upside potential than Keros Therapeutics, Inc., analysts believe Insmed, Inc. is more attractive than Keros Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.5 4 0 INSMInsmed, Inc.17 1 0 -
Is KROS or INSM More Risky?
Keros Therapeutics, Inc. has a beta of 0.857, which suggesting that the stock is 14.332% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.
-
Which is a Better Dividend Stock KROS or INSM?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or INSM?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Keros Therapeutics, Inc.'s net income of -$7.3M is higher than Insmed, Inc.'s net income of -$370M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 2.73x versus 63.30x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.2.73x 10.75x $14.3M -$7.3M INSMInsmed, Inc.63.30x -- $142.3M -$370M
-
Which has Higher Returns KROS or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of -82.06%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M IONSIonis Pharmaceuticals, Inc.96.67% -$0.81 $2.7B -
What do Analysts Say About KROS or IONS?
Keros Therapeutics, Inc. has a consensus price target of $23.00, signalling upside risk potential of 37.97%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $91.13 which suggests that it could grow by 13.06%. Given that Keros Therapeutics, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Keros Therapeutics, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.5 4 0 IONSIonis Pharmaceuticals, Inc.10 6 0 -
Is KROS or IONS More Risky?
Keros Therapeutics, Inc. has a beta of 0.857, which suggesting that the stock is 14.332% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.
-
Which is a Better Dividend Stock KROS or IONS?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or IONS?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Keros Therapeutics, Inc.'s net income of -$7.3M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 2.73x versus 13.72x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.2.73x 10.75x $14.3M -$7.3M IONSIonis Pharmaceuticals, Inc.13.72x -- $156.7M -$128.6M
-
Which has Higher Returns KROS or MNKD?
MannKind Corp. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of 9.72%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About KROS or MNKD?
Keros Therapeutics, Inc. has a consensus price target of $23.00, signalling upside risk potential of 37.97%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 69.81%. Given that MannKind Corp. has higher upside potential than Keros Therapeutics, Inc., analysts believe MannKind Corp. is more attractive than Keros Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.5 4 0 MNKDMannKind Corp.8 0 0 -
Is KROS or MNKD More Risky?
Keros Therapeutics, Inc. has a beta of 0.857, which suggesting that the stock is 14.332% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.839, suggesting its less volatile than the S&P 500 by 16.131%.
-
Which is a Better Dividend Stock KROS or MNKD?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or MNKD?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Keros Therapeutics, Inc.'s net income of -$7.3M is lower than MannKind Corp.'s net income of $8M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while MannKind Corp.'s PE ratio is 60.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 2.73x versus 5.57x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.2.73x 10.75x $14.3M -$7.3M MNKDMannKind Corp.5.57x 60.08x $82.1M $8M
-
Which has Higher Returns KROS or SRPT?
Sarepta Therapeutics, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of -45.06%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B -
What do Analysts Say About KROS or SRPT?
Keros Therapeutics, Inc. has a consensus price target of $23.00, signalling upside risk potential of 37.97%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.43 which suggests that it could grow by 20.49%. Given that Keros Therapeutics, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Keros Therapeutics, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.5 4 0 SRPTSarepta Therapeutics, Inc.7 14 3 -
Is KROS or SRPT More Risky?
Keros Therapeutics, Inc. has a beta of 0.857, which suggesting that the stock is 14.332% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.731%.
-
Which is a Better Dividend Stock KROS or SRPT?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or SRPT?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Keros Therapeutics, Inc.'s net income of -$7.3M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 10.75x while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 2.73x versus 0.76x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.2.73x 10.75x $14.3M -$7.3M SRPTSarepta Therapeutics, Inc.0.76x 20.50x $399.4M -$179.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 17
Cooper-Standard Holdings, Inc. [CPS] is down 3.36% over the past day.
Buy
58
TPH alert for Feb 17
Tri Pointe Homes, Inc. [TPH] is down 0.24% over the past day.
Sell
20
IRON alert for Feb 17
Disc Medicine, Inc. [IRON] is up 17.19% over the past day.
